Prediction tool helps tailor lung cancer screening to patients

May 30, 2018

(HealthDay)—Personalizing the harm-benefit assessment of low-dose computed tomography (LDCT) screening for lung cancer can inform patient-centered screening decisions, according to a study published online May 29 in the Annals of Internal Medicine.

Tanner J. Caverly, M.D., from the University of Michigan in Ann Arbor, and colleagues examined factors that influence when LDCT is patient preference-sensitive using data from two large randomized trials and the Surveillance, Epidemiology, and End Results cancer registry.

In base-case analysis, the researchers found that moderate differences in preferences about the downsides of LDCT screening influenced whether screening was appropriate for eligible persons with annual lung risk <0.3 percent or life expectancy less than 10.5 years. For roughly 50 percent of the study population who were higher-risk eligible persons with longer life expectancy, the benefits of LDCT screening overcame even highly negative views about screening and its downsides. In sensitivity analysis, the researchers noted that rates of false-positive findings and overdiagnosis were not highly influential in determining net benefit and preference sensitivity.

"Identifying circumstances in which LDCT screening is more versus less preference-sensitive may help clinicians personalize their screening discussions, tailoring to both preferences and clinical benefit," the authors write.

Explore further: Vast majority of heavy smokers not screened for lung cancer despite USPSTF recommendations

More information: Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Related Stories

Vast majority of heavy smokers not screened for lung cancer despite USPSTF recommendations

May 17, 2018
An analysis of 1,800 lung cancer screening sites nationwide found that only 1.9% of more than 7 million current and former heavy smokers were screened for lung cancer in 2016, despite United States Preventive Services Task ...

Many pulmonologists under-, over-screen with LDCT

September 28, 2015
(HealthDay)—Almost half of pulmonologists have a propensity for over- or under-use of low-dose computed tomography (LDCT) screening for lung cancer, according to a study published online Sept. 14 in the Annals of the American ...

Risk-based CT screening may reduce deaths from lung cancer

January 1, 2018
Compared to National Lung Screening Trial criteria, targeting screening those at highest risk from lung cancer mortality using a risk prediction tool may improve efficiency in terms of greater reduction in mortality from ...

Strategies presented to avoid overzealous lung CA screening

June 24, 2014
(HealthDay)—The benefits and harms of low-dose computed tomography (LDCT) screening for lung cancer should be carefully considered before Medicare decides on its coverage policy, according to an editorial published online ...

Lung cancer screening found cost-effective for Medicare

October 3, 2014
(HealthDay)—Low-dose computed tomography (LDCT) is a low-cost and cost-effective strategy for screening Medicare beneficiaries for lung cancer, according to a study published in the August issue of American Health & Drug ...

Canadian group gives guideline recommendations for lung cancer screening

September 4, 2013
Lung cancer is the most common cause of cancer death in Ontario. Screening for lung cancer using low-dose computed tomography (LDCT) has been the subject of many research studies since the 1990s. The National Lung Screening ...

Recommended for you

Non-coding DNA reveals a route by which advanced prostate cancer resists treatment

June 15, 2018
Two research teams converge on epigenetic switches that feed treatment-resistant metastatic prostate tumors. This research highlights the value of exploring gene regulation and large-scale structural changes in the cancer ...

Researchers peer inside cells to spy on cancer's on-off switch

June 15, 2018
Forty years after researchers first discovered it in fruit flies, a once-obscure cluster of proteins called PRC2 has become a key target for new cancer-fighting drugs, due to its tendency—when mutated—to bind to and silence ...

PIM-2 protein kinase regulates T-cell activity differently than PIM-1 or PIM-3 isoform

June 15, 2018
The PIM-2 protein kinase negatively regulates T cell responses in transplantation and tumor immunity, while PIM-1 and PIM-3 are positive regulators, report Medical University of South Carolina (MUSC) investigators in an article ...

Gene testing could identify men with prostate cancer who may benefit from immunotherapy

June 14, 2018
Scientists have identified a pattern of genetic changes that could pick out men with advanced prostate cancer who are likely to benefit from immunotherapy.

Without 'yoga and chardonnay' leukemia stem cells are stressed to death

June 14, 2018
Change is stressful. The change that a healthy blood stem cell undergoes to become a leukemia stem cell (LSC) is no exception—think of healthy blood stem cells as young professionals and the transformation into an LSC as ...

Statins found to enhance efficacy of chemotherapy drug in blood cancers

June 14, 2018
A team of researchers with members affiliated with several institutions in the U.S. has found that some statins could enhance the efficacy of a chemotherapy drug used to fight blood cancers in mouse models. In their paper ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.